|
|
| Line 1: |
Line 1: |
| {{BirthControl infobox |
| | #REDIRECT [[Etonogestrel]] |
| | name = Implanon
| |
| | image =
| |
| | width =
| |
| | caption =
| |
| | bc_type = Hormonal<br>Progestin-only implant
| |
| | date_first_use = 1998 (Indonesia)
| |
| | rate_type = Failure
| |
| | perfect_failure% = 0.05
| |
| | typical_failure% = 0.05
| |
| | duration_effect = 3 years
| |
| | reversibility = Yes
| |
| | user_reminders = Requires removal after the 3 years
| |
| | clinic_interval =
| |
| | STD_protection_YesNo = No
| |
| | periods_advantage = Minimizes pain. 20% of women will stop having their period.
| |
| | benefits = Longterm contraception.
| |
| | periods_disadvantage = Various.
| |
| | weight_gain_loss = No proven effect
| |
| | risks =
| |
| | medical_notes =
| |
| }}
| |
| '''Implanon''', made by [[Organon International]], is a single-rod [[Birth control|contraceptive]] subdermal implant that is inserted just under the skin of a woman's upper arm. The 40 mm by 2 mm Implanon rod contains 68 milligrams of the gonane [[progestin]] etonogestrel which is released over a three year period.
| |
| | |
| Peak serum etonogestrel concentrations have been found to reach 781–894 pg/mL in the first few weeks, gradually decreasing to 192–261 pg/mL after 1 year, 154–194 pg/mL after 2 years, and 156–177 pg/mL after 3 years, maintaining ovulation suppression and contraceptive efficacy.<ref name=fda_label>{{cite web | url=http://www.fda.gov/cder/foi/label/2006/021529lbl.pdf | title=Implanon label | publisher=FDA | format=PDF | date=2006-07-17 | accessdate=2006-08-23}}</ref> Implanon may be removed at any time, but must be removed after three years.
| |
| | |
| Implanon was first approved for use in [[Indonesia]] in 1998, was subsequently approved for use in over 30 other countries, and has been used by over 2.5 million women worldwide. Implanon was approved for use in the [[United States]] by the [[FDA]] on [[July 17]], [[2006]].
| |
| | |
| ==Mechanism of action==
| |
| The mechanism of action of progestin-only contraceptives depends on the progestin activity and dose.<!--
| |
| --><ref name=glasier>{{cite book |last=Glasier |first=Anna |editor=DeGroot, Leslie J.; Jameson, J. Larry (eds.) |title=Endocrinology |edition=5th ed. |year=2006 |publisher=Elsevier Saunders |location=Philadelphia |id=ISBN 0-7216-0376-9 |pages=pp. 3000-1 |chapter=Contraception}}</ref> Intermediate dose progestin-only contraceptives, like Implanon (and the progestin-only pill Cerazette) allow some follicular development but inhibit ovulation in almost all cycles as the primary mechanism of action. Ovulation was not observed in studies of Implanon in the first two years of use and only rarely in the third year with no pregnancies. A secondary mechanism of action is the progestogenic increase in cervical mucus viscosity which inhibits sperm penetration.<!--
| |
| --><ref name="implanon spc">{{cite web |author=[[Organon International|Organon]] |month=April |year=2006 |title=Implanon SPC (Summary of Product Characteristics) |url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=5382 |accessdate=2007-04-15}}</ref>
| |
| Hormonal contraceptives also have effects on the endometrium that theoretically could affect implantation, however no scientific evidence indicates that prevention of implantation actually results from their use.<!--
| |
| --><ref>{{cite journal |author=Rivera R, Yacobson I, Grimes D |year=1999 |title=The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices |journal=Am J Obstet Gynecol |volume=181 |issue=5 Pt 1 |pages=1263-9 |id=PMID 10561657}}</ref>
| |
| ==Insertion==
| |
| Local [[anaesthetic]] is applied to the upper arm, and then a needle-like applicator is used to insert the implanon rod under the skin. The procedure can take less than a minute. An experienced clinician is required for proper insertion, to minimize the risk of nerve damage,<ref>{{cite journal | author=Wechselberger G, Wolfram D, Pulzl P, Soelder E, Schoeller T | title=Nerve injury caused by removal of an implantable hormonal contraceptive | journal=Am J Obstet Gynecol | year=2006 | month=July | volume=195 | issue=1 | pages=323-6 | id=PMID 16813761}}</ref> or misplacement which could result in unintended pregnancy. Implant site complications are experienced by 3.6% of patients, and include swelling, redness, hematoma and pain.
| |
| | |
| ==Side effects and risks==
| |
| There are notable [[side effect]]s caused by Implanon that occur in some women. Irregular [[Menstrual cycle|periods]], [[headache]]s, [[Acne vulgaris|acne]], weight gain and abdominal pain were among the most commonly reported side effects in clinical trials.
| |
| | |
| Eleven percent of women had Implanon removed because of irregular menstrual bleeding, which can include excessive menstrual bleeding. Some women may have no menstrual period at all while using Implanon.<ref name="reuters">{{cite news | author =Susan Heavey & Lisa Richwine | url =http://today.reuters.com/News/newsArticle.aspx?type=healthNews&storyID=2006-07-18T205203Z_01_L18815482_RTRUKOC_0_US-CONTRACEPTIVE.xml&pageNumber=0&imageid=&cap=&sz=13&WTModLoc=NewsArt-C1-ArticlePage3 | title =New implantable contraceptive for women gets go-ahead | work =[[Reuters]] | date =Jul 18, 2006}}</ref>
| |
| | |
| It is not known whether Implanon changes a woman's risk for breast cancer.<ref name=fda_label/><ref name=patient_inf>{{cite web | url=http://www.implanon-usa.com/authfiles/images/543_174732.pdf | title=Implanon patient information | publisher=Organon USA Inc. | format=PDF | year=2006 | month=July | accessdate=2006-08-23}}</ref>
| |
| | |
| Failure rate for Implanon was reported at 0.1%. Most cases of failure were due to incorrect insertion or insertion during pregnancy. In comparison, surgical sterilization has a failure rate of 0.2%.<ref name=fpahealth>{{cite web | url=http://www.fpahealth.org.au/news/20030211_implanon2.html | title=Implanon effectiveness}}</ref>
| |
| | |
| Undesirable effects that may occur include acne, headache, weight gain, breast tenderness, hair loss, mood changes, changes in libido, and abdominal pain. Vaginal bleeding may occur at irregular intervals during the use of Implanon. Some patients do not experience any bleeding at all. It is important to have regular medical check ups, because while irregular bleeding is a common side effect of Implanon, it may rarely be caused by other medical conditions.
| |
| | |
| == Fertility after Implanon ==
| |
| | |
| Within a few days of having Implanon removed the hormones released by Implanon will have left the body. The chances of becoming pregnant should be the same as they were before using Implanon.
| |
| | |
| ==Complications==
| |
| | |
| Complications which can occur include:
| |
| | |
| * impalpability of implant
| |
| * broken or damaged implant
| |
| * slight migration
| |
| * fibrosis.
| |
| | |
| If Implanon is "impalpable"—cannot be felt—an ultrasound must be performed. Surgery under local or general anesthesia may be required to remove an impalpable Implanon implant, especially if it is broken, damaged, has migrated, or is deeply embedded in scar tissue or [[fibrosis]].
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| ==External links==
| |
| *[http://www.implanon.com Official website]
| |
| | |
| {{BirthControl}}
| |
| | |
| [[Category:Hormonal contraception]]
| |
| | |
| [[de:Implanon]]
| |
| [[nl:Etonogestrel implantatiestaafje]]
| |
| [[pt:Implanon]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |